ArticleArchives of pharmacal research2026
Nobiletin attenuates LPS-induced acute lung injury via a STING-dependent signaling pathway.
Article in Archives of pharmacal research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Previous studies have shown that Quzhou Fructus Aurantii extract (QFAEE) ameliorates lipopolysaccharide (LPS)-induced acute lung injury (ALI) by modulating the Stimulator of interferon genes (STING) pathway. Nevertheless, the mechanisms underlying the anti-inflammatory effects of nobiletin (Nob), the primary bioactive component of QFAEE, have not been clearly elucidated. The present study aimed to investigate the protective effects of Nob on a mouse model of LPS-induced ALI and elucidate its underlying mechanism. The pulmonary inflammatory response in mice was quantified by performing fluorescence-based RT‒qPCR, bronchoalveolar lavage fluid (BALF) cell counting, and hematoxylin‒eosin (HE) staining. Transcriptomic profiling was performed to explore the mechanisms by which Nob ameliorates LPS-induced ALI. The anti-inflammatory mechanisms were further elucidated using western blotting, immunohistochemical staining, cellular thermal shift assays (CETSAs), and microscale thermophoresis. Functional validation was conducted using the STING agonist vadimezan (DMXAA), the STING inhibitor SN-001, and STING-knockout (STING-KO) mice. Nobiletin-loaded liposomes (Nob-Lipo) significantly attenuated LPS-induced pulmonary inflammation in mice. The results of the transcriptomic analysis suggested that this protective effect was associated with the modulation of the type I interferon pathway. In RAW264.7 and THP-1 cells, pretreatment with Nob effectively attenuated the interferon regulatory factor 3 (IRF3)-mediated type I interferon response and nuclear factor kappa-B (NF-κB)-dependent proinflammatory cytokine expression following DMXAA-induced STING pathway activation. Furthermore, the STING inhibitor SN‑001 markedly suppressed LPS‑induced inflammatory responses, as evidenced by significantly reduced levels of proinflammatory cytokines and interferon‑stimulated genes, and effectively blocked the nuclear translocation of NF‑κB and IRF3. Notably, after inhibitor treatment, Nob no longer exerted its previously observed anti‑inflammatory effects, further supporting the critical regulatory role of STING in LPS‑mediated inflammation and indicating that the anti‑inflammatory activity of Nob is primarily dependent on the STING pathway. Moreover, in STING‑KO mice with LPS‑induced ALI, the loss of the protective effect of Nob further confirmed that its anti‑inflammatory activity depends on STING, highlighting the essential role of STING signaling in mediating its protective effects. In conclusion, the protective effect of Nob on an LPS-induced ALI model is mediated primarily through the modulation of STING signaling.
Indexed as
Identifiers
42257824What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.